# Walgreens Boots Alliance account plan

> Walgreens Boots Alliance: US pharmacy, Boots and healthcare group, $147.7 billion of sales in fiscal 2024, private under Sycamore Partners since August 2025.

## At a glance

Walgreens Boots Alliance (WBA) is a pharmacy-led health and retail group whose brands include Walgreens, Duane Reade, Boots and Benavides. In fiscal 2024 (year ended August 31, 2024) it had sales of $147.7 billion, a net loss attributable to WBA of $8.6 billion and approximately 312,000 employees. On August 28, 2025 it was acquired by affiliates of Sycamore Partners, in partnership with Stefano Pessina and his family, who reinvested 100% of their interests, and its stock was delisted from Nasdaq. Following the closing, Walgreens, The Boots Group, Shields Health Solutions, CareCentrix and VillageMD operate as separate standalone companies, according to the closing press release; Walgreens is led by CEO Mike Motz.

## Business units

- **U.S. Retail Pharmacy (Walgreens)** ($115.8 billion of fiscal 2024 sales): Walgreens and Duane Reade drugstores, specialty and home delivery pharmacy, with 8,560 retail and healthcare locations at August 31, 2024. Pharmacy was 77% of segment sales and Retail 23%; 796 million prescriptions were filled. In the quarter to May 31, 2025 sales rose 7.8% to $30.7 billion while locations fell to 8,160 from 8,595 as stores closed.
- **International (Boots and German wholesale)** ($23.6 billion of fiscal 2024 sales): Boots stores in the UK, the Republic of Ireland and Thailand, Benavides in Mexico, and a pharmaceutical wholesale business in Germany, which was 51% of segment sales. In the quarter to May 31, 2025 sales rose 7.8% to $6.2 billion, with Boots.com sales up 18.7%. Led by Ornella Barra, Chief Operating Officer, International. The closing release lists The Boots Group as a separate standalone company.
- **U.S. Healthcare (VillageMD, Shields, CareCentrix)** ($8.3 billion of fiscal 2024 sales): A majority position in VillageMD (value-based primary, multi-specialty and urgent care), Shields Health Solutions (specialty pharmacy for hospitals), CareCentrix (post-acute and home care management) and the organic Walgreens Health business. VillageMD was 75% of segment sales in fiscal 2024. In the quarter to May 31, 2025 VillageMD sales fell 6.5% while CareCentrix rose 11.6% and Shields 24.8%.

## Strategic priorities

- **Core pharmacy and retail focus**: On closing, Walgreens CEO Mike Motz said the company is renewing its focus on its core pharmacy and retail platform, its stores and its customer experience. The fiscal 2024 10-K had already set a strategic review to build the core retail and specialty pharmacy business.
- **Store footprint optimization**: The Footprint Optimization Program, approved on October 14, 2024, plans to close approximately 900 to 1,000 stores primarily across the U.S. by the end of fiscal 2027, or 1,200 to 1,300 stores including those left from the earlier program.
- **Stabilising pharmacy margins with PBMs**: The U.S. Retail Pharmacy action plan includes collaborating and negotiating with PBMs to bring more stability to reimbursement, assessing provider status and new payment arrangements, and expanding owned brands in key categories.
- **Cost savings and cash discipline**: The Transformational Cost Management Program reached annual savings of $4.5 billion at the end of fiscal 2024. Capital expenditure was cut by over $700 million in fiscal 2024 and net debt reduced by nearly $2.0 billion; the quarterly dividend was suspended on January 30, 2025.
- **Healthcare and in-store operations**: Before the sale, CEO Tim Wentworth said investments would continue in multi-fulfillment sites to free up clinical time in stores, digital check-in and store resets, and that Sycamore expects WBA's team to lead the healthcare side.
- **Monetising VillageMD interests**: Shareholders received one Divested Asset Proceed Right per share, worth up to $3.00 each from 70% of net proceeds of any monetisation of WBA's equity or debt interests in VillageMD.

## Latest results

In the third quarter of fiscal 2025 (three months ended May 31, 2025), the last periodic report before the sale, sales were $38,986 million, up 7.2%, and operating income was $53 million versus $111 million a year earlier. Net loss attributable to WBA was $175 million and adjusted diluted EPS was $0.38 versus $0.63. U.S. Retail Pharmacy pharmacy sales rose 11.8% but retail sales fell 5.3%; U.S. Healthcare adjusted operating income was $54 million versus a loss of $22 million. Over nine months, 423 stores were closed. No guidance is given and WBA no longer reports publicly after the August 28, 2025 closing.

## Investments and deals

- **Footprint Optimization Program**: Estimated cumulative pre-tax charges of approximately $2.2 billion to $2.4 billion, with $473 million recognised since inception as of May 31, 2025.
- **Sycamore acquisition**: Total cash payable to equityholders at closing was approximately $8.25 billion, at $11.45 per share, funded by Sycamore-affiliated funds, debt financing and reinvestment by Stefano Pessina.
- **Healthcare assets**: VillageMD acquired Summit Health in fiscal 2023 (net of cash acquired $6.7 billion). VillageMD took a $12.4 billion goodwill impairment in fiscal 2024 and WBA signed a forbearance agreement on its $2.25 billion secured loan on August 6, 2024.
- **Financing and asset sales**: A $2.5 billion accounts receivable facility was set up on April 24, 2025, and approximately $2.7 billion of Cencora shares were sold in fiscal 2024.

## Challenges and risks

- **Reimbursement pressure and payor concentration**: Three third-party payors were approximately 34% of consolidated sales in fiscal 2024, and WBA reports continuing reimbursement pressure from PBMs and government plans.
- **Weak retail sales**: U.S. Retail Pharmacy retail sales fell 4.6% in fiscal 2024 and 5.3% in the quarter to May 31, 2025, weaker in grocery and household, health and wellness, and beauty.
- **Impairments and losses**: Fiscal 2024 included a $12.7 billion goodwill impairment and a net loss attributable to WBA of $8.6 billion; the nine months to May 31, 2025 added $4.3 billion of impairment charges attributable to WBA.
- **Opioid liabilities**: WBA accrued a $6.6 billion liability for opioid-related claims, with payments over the next 15 years.
- **Single wholesaler dependence**: The 10-K lists reliance on one wholesaler, Cencora, as primary source of branded and generic drugs as a risk.

## What leadership says

> "we are renewing our focus on our core pharmacy and retail platform, our stores and our customer experience" — Mike Motz, Chief Executive Officer, Walgreens, Walgreen Co. press release on the closing of the Sycamore acquisition, August 28, 2025

> "move with certainty, speed and focus" — Stefan Kaluzny, Managing Director, Sycamore Partners, Walgreen Co. press release, August 28, 2025

> "arguably we're in the first third of a turnaround" — Tim Wentworth, former Chief Executive Officer, Walgreens Boots Alliance, U.S. Town Hall, March 7, 2025

> "every dollar we spend is spent toward growing the business or running it effectively" — Tim Wentworth, former Chief Executive Officer, Walgreens Boots Alliance, Employee town hall, May 8, 2025


## Where a supplier can help

- **Store closure and real estate execution**: Tied to the Footprint Optimization Program (900 to 1,000 stores by the end of fiscal 2027): lease exit, asset disposal, prescription transfer and workforce transition services.
- **Pharmacy reimbursement and PBM analytics**: Tied to the margin pressure and payor concentration: tools for contract modelling, claims reconciliation and network performance across PBMs.
- **Retail turnaround and assortment tools**: Tied to the focus on stores and customer experience and the fall in retail sales: assortment, pricing and promotion, shrink reduction and store-level analytics.
- **Standalone company set-up**: Tied to Walgreens, Boots, Shields, CareCentrix and VillageMD running as separate companies: separation of IT, finance, procurement and shared services.
- **Healthcare services and fulfillment**: Tied to the priority on freeing clinical time (multi-fulfillment sites, digital check-in) and the Walgreens Health, Shields and CareCentrix businesses: automation, patient engagement and care coordination software.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Walgreens Boots Alliance, Inc. Form 10-K for fiscal 2024 (year ended August 31, 2024)](https://www.sec.gov/Archives/edgar/data/1618921/000161892124000084/wba-20240831.htm)

Annual report · 2024-10-15

- Last annual report Walgreens Boots Alliance (WBA) filed as a listed company: sales of $147.7 billion in fiscal 2024 (+6.2%), about 312,000 employees, a presence in 8 countries and approximately 12,500 locations across the U.S., Europe and Latin America.
- Three reportable segments: U.S. Retail Pharmacy ($115.8 billion of sales, the Walgreens business), International ($23.6 billion, Boots and a German wholesale business) and U.S. Healthcare ($8.3 billion, VillageMD, Shields, CareCentrix).
- Heavy losses: net loss attributable to WBA of $8.6 billion (diluted loss of $10.01 per share), including a $12.7 billion goodwill impairment, mostly VillageMD; adjusted diluted EPS was $2.88, down 27.6%.
- U.S. Retail Pharmacy: pharmacy sales up 8.2% but retail sales down 4.6%; adjusted operating income fell 41.3% to $2.2 billion on a challenging retail environment and net reimbursement pressure.
- Strategic review under CEO Tim Wentworth (CEO since October 2023): focus on core retail and specialty pharmacy, a Footprint Optimization Program to close approximately 900 to 1,000 stores primarily across the U.S. by the end of fiscal 2027, own-brand merchandising, PBM negotiations, and an assessment of the dividend policy.
- Cash discipline: capital expenditure cut by over $700 million to $1.4 billion, net debt reduced by nearly $2.0 billion, $4.5 billion of annual savings reached under the Transformational Cost Management Program.
- Risks named: reimbursement pressure from PBMs and payors (three third-party payors were approximately 34% of consolidated sales), a single wholesaler (Cencora) supplying drugs, opioid settlements ($6.6 billion liability), and VillageMD's cash needs (loan in default, forbearance signed on August 6, 2024).
- Customer-facing assets: approximately 124 million myWalgreens members, about 15 million active Boots Advantage Card members, and more than 89,000 healthcare service providers in the U.S. segment.

### [Walgreens Boots Alliance, Inc. Form 10-Q for the third quarter of fiscal 2025 (three months ended May 31, 2025)](https://www.sec.gov/Archives/edgar/data/1618921/000161892125000056/wba-20250531.htm)

Interim report · 2025-06-26

- Last periodic report WBA filed before it was taken private: third quarter of fiscal 2025 (three months ended May 31, 2025). Sales were $38,986 million (+7.2%); operating income $53 million; net loss attributable to WBA $175 million ($0.20 per share); adjusted diluted EPS $0.38 versus $0.63 a year earlier.
- Nine months to May 31, 2025: sales $117,034 million (+6.3%), net loss $3.3 billion including $4.3 billion of non-cash impairment charges attributable to WBA (goodwill, intangibles and long-lived assets, mainly U.S. Retail Pharmacy and VillageMD).
- U.S. Retail Pharmacy: quarterly sales +7.8% to $30.7 billion (pharmacy +11.8%, retail -5.3%); adjusted operating income $350 million; locations down to 8,160 from 8,595 as the Footprint Optimization Program proceeds (423 stores closed in nine months).
- International: sales +7.8% to $6.2 billion; Boots UK sales +5.0% and Germany wholesale +6.8% on a constant currency basis; Boots.com sales +18.7%, 17 percent of Boots UK retail sales; adjusted operating income +22.0% to $214 million.
- U.S. Healthcare: sales $2.1 billion; VillageMD sales -6.5%, CareCentrix +11.6%, Shields +24.8%; adjusted operating income of $54 million versus a loss of $22 million.
- Pending merger: signed March 6, 2025 with affiliates of Sycamore Partners at $11.45 per share in cash plus a Divested Asset Proceed Right worth up to $3.00; go-shop expired April 10, 2025 with no superior proposal; special meeting scheduled July 11, 2025; closing expected in the third or fourth quarter of calendar 2025.
- Financing moves: a $2.5 billion accounts receivable facility (April 24, 2025) used to repay $2.0 billion of term loans; dividend suspended on January 30, 2025.

### [Form 8-K and press releases on completion of the Sycamore Partners acquisition of Walgreens Boots Alliance (August 28, 2025)](https://www.sec.gov/Archives/edgar/data/1618921/000119312525190603/d87240d8k.htm)

Report · 2025-08-28

- On August 28, 2025 Blazing Star Merger Sub merged into Walgreens Boots Alliance, Inc. (WBA), which survived as a wholly owned subsidiary of Blazing Star Parent, affiliates of investment funds managed by Sycamore Partners; WBA stock and listed notes ceased trading on Nasdaq that day and WBA said it intended to file Form 15 to end its SEC reporting.
- Consideration: $11.45 in cash per share plus one Divested Asset Proceed Right (up to $3.00 per right from 70% of net proceeds of monetising WBA's stake in VillageMD); total cash payable to equityholders at closing was approximately $8.25 billion.
- Funding came from Sycamore-affiliated fund equity, debt financing, and reinvestment by Stefano Pessina and his affiliated entities; the Pessina family reinvested 100% of its interests in WBA.
- Structure after closing, per the press releases: Walgreens, The Boots Group, Shields Health Solutions, CareCentrix and VillageMD operate as separate standalone companies under private ownership.
- Walgreens leadership: Mike Motz, formerly CEO of Staples US Retail and earlier President of Shoppers Drug Mart, became CEO of Walgreen Co. immediately, replacing Tim Wentworth (who stays as a Director); John Lederer became Executive Chairman of Walgreens.
- Walgreens describes itself as serving nearly 9 million customers and patients each day across approximately 8,500 stores in the U.S. and Puerto Rico with approximately 220,000 team members, nearly 90,000 of them healthcare service providers.
- Walgreens CEO Motz: "we are renewing our focus on our core pharmacy and retail platform, our stores and our customer experience".

### [U.S. Town Hall with CEO Tim Wentworth on the Sycamore transaction (transcript filed with the SEC)](https://www.sec.gov/Archives/edgar/data/1618921/000119312525049933/d882386ddefa14a.htm)

Executive talk · Tim Wentworth, Chief Executive Officer, Walgreens Boots Alliance · 2025-03-07

- Wentworth told U.S. team members the day after the Sycamore deal was announced that WBA is "arguably we're in the first third of a turnaround" and that the sale is meant to de-risk execution for shareholders, communities and employees.
- He pitched Sycamore as an owner that understands retail, is "unafraid to take risks to save brands", believes consumer healthcare is the future, and has few staff, so it looks to management to execute rather than sending "an army to fix things".
- He expected closing in the fourth quarter of 2025 because of regulatory approvals and the need to relicense stores under a new name; until then WBA stays publicly traded and operates as before.
- Deal terms he restated: $11.45 in cash plus a right to up to $3 of future value as City, Summit and VillageMD are monetised, with 70% of the first dollars of any sale or monetization going to investors.
- Operating commitments: continued cost savings and capital management, continued use of multi-fulfillment sites to free up clinical time in stores, digital check-in, store resets, and a top management meeting planned for September for a thousand plus people in Chicago.
- After closing, WBA would still operate as Walgreens, Boots and the other brand names (Shields, CareCentrix), with its global headquarters kept in Chicagoland.
- He said Sycamore "does not pretend to have healthcare knowledge" and is counting on WBA to lead the healthcare part.

### [Walgreens employee town hall of May 8, 2025: CEO Tim Wentworth on the Sycamore transaction (excerpt filed with the SEC)](https://www.sec.gov/Archives/edgar/data/1618921/000119312525116076/d939695ddefa14a.htm)

Executive talk · Tim Wentworth, Chief Executive Officer, Walgreens Boots Alliance · 2025-05-08

- Wentworth called Sycamore "the most compelling opportunity for value creation and growth that we could possibly have" and said it was "not the only path for us" but "absolutely the best path".
- He said Sycamore told him "we don't run companies. We support management", and that it is supportive of continued investment in the teams.
- Deal progress: the go-shop period ended the month before with no credible alternative interest; a preliminary proxy had been filed with the SEC; shareholder vote expected "sometime this summer"; closing before the end of the year.
- He said WBA's headquarters would stay in the state and that the company had committed to continuing to grow.
- He compared the move to other well-known companies that were private or returned to public markets (Dell, HCA, Hilton) and argued that Wall Street "doesn't believe that we can be Amazon" or collaborate with PBMs, while he said it was wrong.
- Message to staff: stay focused on customers and each other, and be sure that "every dollar we spend is spent toward growing the business or running it effectively".

## Questions about Walgreens Boots Alliance

### Who owns Walgreens Boots Alliance?

Affiliates of Sycamore Partners acquired it on August 28, 2025, in partnership with Stefano Pessina and his family, who reinvested 100% of their interests. Its stock no longer trades on Nasdaq.

### How big is Walgreens Boots Alliance?

In fiscal 2024 it had sales of $147.7 billion and approximately 312,000 employees. At the closing, Walgreens described approximately 8,500 stores in the U.S. and Puerto Rico and approximately 220,000 team members.

### How is the group organised now?

The closing press release says Walgreens, The Boots Group, Shields Health Solutions, CareCentrix and VillageMD operate as separate standalone companies. Before the sale WBA reported three segments: U.S. Retail Pharmacy, International and U.S. Healthcare.

### Who leads Walgreens?

Mike Motz became CEO of Walgreens on August 28, 2025, replacing Tim Wentworth, who stays as a Director. John Lederer is Executive Chairman of Walgreens.

### What is Walgreens' strategy?

Renewed focus on the core pharmacy and retail platform, stores and customer experience, together with a program to close approximately 900 to 1,000 stores primarily across the U.S. by the end of fiscal 2027.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-19)_
